Highlights of This Issue 5603

SPECIAL FEATURES

CCR Translations

5605 Heading in a New Direction: Drug Permeability in Breast Cancer Brain Metastasis
George W. Sledge, Jr.
See article p. 5664

CCR New Strategies

5608 New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies
Kieron Dunleavy, Richard L. Piekarz, Jasmine Zain, John E. Janik, Wyndham H. Wilson, Owen A. O’Connor, and Susan E. Bates

Molecular Pathways

5618 The Molecular Basis of Lmo2-Induced T-Cell Acute Lymphoblastic Leukemia
David J. Curtis and Matthew P. McCormack

5624 Targeting Hypoxic Cells through the DNA Damage Response
Monica Olcina, Philip S. Lecane, and Ester M. Hammond

HUMAN CANCER BIOLOGY

5630 Benign Mesenchymal Stromal Cells in Human Sarcomas

5641 Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti, Luca Agnelli, Fortunato Morabito, Giovanna Cutrera, Adrian Andronache, Serena Matti, Francesco Ferrari, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festa, Stefano Molica, Giorgio Lambertenghi Delliliers, Silvio Bicciato, Manlio Ferrarini, and Antonino Neri

Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box–Binding Protein 1, and E-Cadherin Regulation
Masaki Shiota, YooHyun Song, Akira Yokomizo, Keijiro Kiyoshima, Yasuhiro Tada, Hiroshi Uchino, Takeshi Ichiumi, Junichi Inokuchi, Yoshinao Oda, Kentaro Kuroiwa, Katsunori Tatsugi, and Seiji Naito

5664 Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman, Rajendran K. Mittapalli, Kunal S. Taskar, Vinay Rudraraju, Brunilde Gril, Kaci A. Bohn, Chris E. Adkins, Amanda Roberts, Helen R. Thorsheim, Julie A. Caasch, Suyun Huang, Diane Palmieri, Patricia S. Steeg, and Quentin R. Smith
See commentary p. 5605

5679 Quercetin Induces Tumor-Selective Apoptosis through Downregulation of Mcl-1 and Activation of Bax
Senping Cheng, Ning Gao, Zhen Zhang, Gang Chen, Amit Budhraja, Zanji Ke, Young-ek Son, Xin Wang, Jia Luo, and Xianglin Shi
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma

Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice
Lucia Fini, Giulia Piazz, Claudio Ceccarelli, Yahya Daoud, Andrea Belluzzi, Alessandra Munarini, Giulia Graziani, Vincenzo Fogliano, Melissa Garcia, Antonio Gasbarrini, Robert M. Genta, C. Richard Boland, and Luigi Ricciardiello

Noninvasive Radiofrequency Field Destruction of Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles
Evan S. Glazer, Cihui Zhu, Kathryn L. Massey, C. Shea Thompson, Warna D. Kaluarachchi, Amir N. Hamir, and Steven A. Curley

Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses
Ling-Yuan Kong, Adam S. Wu, Tiffany Doucette, Wei-Qiao, Raymond Sawaya, Ganesh Rao, and Amy B. Heimberger

TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
Dominic Stadel, Andrea Mohr, Caroline Ref, Marion MacFarlane, Xiaohou Zhou, Robin Humphreys, Max Bachem, Gerry Cohen, Peter Möller, Ralf M. Zwacka, Klaus-Michael Debatin, and Simone Fulda

Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
Wei-meng Zhao, Lihong Wang, Hangil Park, Sophea Chhim, Melanie Tanphanich, Masakazu Yashiro, and K. Jin Kim

DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer
Brian M. Alexander, Kam Sprott, D. Allan Farrow, Xiao Zhe Wang, Alan D. D’Andrea, Stuart J. Schmitt, Laura C. Collins, David T. Weaver, and Judy E. Garber

High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
Steven C.H. Kao, Nick Pavlakis, Rozelle Harvie, Janette L. Vardy, Michael J. Boyer, Nico van Zandwijk, and Stephen J. Clarke

Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion
Takeo Kosaka, Eiji Kikuchi, Shuji Mikami, Akira Miyajima, Suguru Shirotaka, Masaru Ishida, Yasunori Okada, and Mototsugu Oya
Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett’s Associated Esophageal Adenocarcinoma

Giang Huong Nguyen, Aaron J. Schetter, David B. Chou, Elise D. Bowman, Ronghua Zhao, Jason E. Hawkes, Ewy A. Mathe, Kensuke Kumamoto, Yiqiang Zhao, Anuradha Budhu, Nobutoshi Hagiwara, Xin Wei Wang, Masao Miyashita, Alan G. Casson, and Curtis C. Harris

Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers

Carolyn M. Slupsky, Helen Steed, Tiffany H. Wells, Kelly Dabbs, Alexandra Schepansky, Valerie Capstick, Wylam Faught, and Michael B. Sawyer

Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples

Vera L. Costa, Rui Henrique, Stine A. Danielsen, Sara Duarte Pereira, Mette Eknaes, Rolf I. Skotheim, Angelo Rodrigues, José S. Magalhães, Jorge Oliveira, Ragnhild A. Lothe, Manuel R. Teixeira, Carmen Jerónimo, and Guro E. Lind

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials


Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Michele Del Vecchio, Roberta Montarini, Stefania Canova, Lorenzo Di Guardo, Nicola Pimpinelli, Mario R. Sottoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone, Emilio Bajetta, and Andrea Anichini

Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment


Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates ALK as a Novel Drug Target for Neuroblastoma

Correction: Systems-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates ALK as a Novel Drug Target for Neuroblastoma
Brain metastases of breast cancer are associated with significant morbidity and mortality. In their study, Lockman and colleagues quantified permeability, and paclitaxel and doxorubicin uptake in over 2000 experimental brain metastatic lesions from two model systems. The representative image shown on the cover is a multimodal image illustrating a single metastatic brain lesion which has 10 fold greater permeability compared to that of normal brain. Despite the increased permeability, drug accumulation only reached cytotoxic levels (>1000 ng/g) in a small subset of metastatic lesions, indicating that new brain-permeable drugs will be required. The picture was obtained by multichannel imaging of the eGFP MDA-MB-231Br lesion (green), indocyanine green within the vasculature (yellow), and 14C-AIB phosphorescence (red). For further details, please see Lockman and coworkers on page 5664 in this issue.